Clinical trials: Neoplasm, Bronchial
NSCLC (Advanced Non-small Cell Lung Cancer)
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
This study aims to evaluate the safety and efficacy of SCTB41 combined with docetaxel in patients with previously treated non-small cell lung cancer. The Phase II part of this study is an open-label, multicenter clinical trial.
- Trial name
- NCT07609251
- Testing
- SCTB41, docetaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sinocelltech Ltd.
Non Small Cell Lung Cancer
Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients
A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer
- Trial name
- NCT00350792
- Testing
- pemetrexed, carboplatin
- Where
- 7 sites in France
- Volunteers
- 62 people
- Sponsor
- Eli Lilly and Company
Non-Small-Cell Lung Cancer
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC
- Trial name
- KYLIN-1 (NCT06343064)
- Testing
- Vebreltinib, PLB1004
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Carcinoma, Non-Small Cell Lung
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
- Trial name
- ARTEMIDELung04 (NCT06868277)
- Testing
- Rilvegostomig, Pembrolizumab
- Where
- 304 sites in United States, Argentina and 25 more
- Volunteers
- 830 people
- Sponsor
- AstraZeneca
Extensive-stage Small Cell Lung Cancer
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
Phase II Study is to Evaluate the Safety and tolerability of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.
- Trial name
- NCT04254471
- Testing
- AL3810, carboplatin + etoposide
- Where
- China
- Volunteers
- 313 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Extensive-stage Small-cell Lung Cancer
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with extensive-stage small cell lung cancer.
- Trial name
- NCT06437509
- Testing
- BL-B01D1, PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Study of PX-866 and Docetaxel in Solid Tumors
Phase 1: To determine the maximally tolerated dose (MTD) or recommended dose (RD) and any potential efficacy of PX-866 in combination with docetaxel in patients with solid tumors.
- Trial name
- NCT01204099
- Testing
- Docetaxel, PX-866
- Where
- 33 sites in United States, Canada
- Volunteers
- 223 people
- Sponsor
- Cascadian Therapeutics Inc.
Non-small Cell Lung Cancer
A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT06114511
- Testing
- BL-M07D1
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
This 2 arm study will evaluate the management of Tarceva-induced skin rash in patients with non-small cell lung cancer who have failed first-line chemotherapy for advanced disease.
- Trial name
- NCT00531934
- Testing
- Doxycline, erlotinib [Tarceva]
- Where
- 24 sites in France
- Volunteers
- 147 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
The objective of the study is to evaluate the safety and tolerability of SI-B036 in participants with solid tumors who have received at least one prior line of therapy for advanced disease.
- Conditions
- Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer
- Trial name
- NCT07857616
- Testing
- SI-B036
- Where
- 7 sites in United States
- Volunteers
- 424 people
- Sponsor
- SystImmune Inc.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) to find out whether it is safe for Chinese participants who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT06549816
- Testing
- sigvotatug vedotin
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Lung Cancer, Small Cell
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
The purpose of this study is to determine the bioequivalence of the new oral capsule formulation to the currently used oral capsule formulation of topotecan.
- Trial name
- NCT00259935
- Testing
- topotecan
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
The purpose of this study is to describe the clinical and health-related outcomes of amivantamab-containing regimens for the treatment of common epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC…
- Trial name
- LEPIDOPTERA (NCT07230691)
- Where
- 86 sites in Austria, Belgium and 6 more
- Volunteers
- 380 people
- Sponsor
- Janssen Research & Development, LLC
Brain Tumor, Non Small Cell Lung Cancer
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA…
- Trial name
- LIMITLESS (NCT05317858)
- Testing
- Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 96 people
- Sponsor
- InSightec
Metastatic Non-small Cell Lung Cancer
Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC
The study is a single-arm, multi-center, open-label clinical trial. The study aims to expand the sample size based on the fixed dose recommended by the results of previous dose exploration studies in order to further evaluate the…
- Trial name
- NCT03300115
- Testing
- AC0010
- Where
- 25 sites in China
- Volunteers
- 222 people
- Sponsor
- Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
The goal of this clinical trial is to compare the amount of study drug in patients' blood to confirm that SB27 works in the same way as EU and US sourced Keytruda in early or locally advanced non-small cell lung cancer (NSCLC)…
- Trial name
- NCT06268613
- Testing
- SB27, EU sourced Keytruda, US sourced Keytruda
- Where
- 24 sites in Poland, South Korea and 2 more
- Volunteers
- 163 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.
- Trial name
- NCT02954991
- Testing
- Glesatinib, Sitravatinib, Mocetinostat
- Where
- 25 sites in United States
- Volunteers
- 161 people
- Sponsor
- Mirati Therapeutics Inc.
Small Cell Lung Cancer (SCLC)
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
The purpose of this study is to assess the safety and efficacy of pembrolizumab plus standard of care (SOC) chemotherapy (etoposide/platinum [EP]) in participants with newly diagnosed extensive stage small cell lung cancer…
- Trial name
- NCT03066778
- Testing
- Pembrolizumab, Normal saline solution, Carboplatin
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 453 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.
To assess the antitumour activity (response rate) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) of two different combinations of docetaxel and gemcitabine and of a sequential treatment of…
- Trial name
- NCT00425191
- Testing
- Docetaxel and Gemcitabine, Gemcitabine cisplatin followed by docetaxel
- Where
- Italy
- Volunteers
- 165 people
- Sponsor
- Sanofi
Carcinoma, Non-Small-Cell Lung
Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer
This study will evaluate progression free survival (PFS), overall survival (OS), objective response rate (ORR), duration of response, and safety of motesanib (AMG706) in combination with paclitaxel and carboplatin compared to…
- Trial name
- NCT02629848
- Testing
- Motesanib, Paclitaxel, Carboplatin
- Volunteers
- 401 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.